Moleculin Biotech Secures $5.8 Million Through Warrant Exercise Moleculin Biotech, a late-stage pharmaceutical firm, announces the exercise of warrants generating $5.8 million to advance its cancer treatments.

Moleculin Biotech Secures $5.8 Million Through Warrant Exercise #United_States #Houston #Annamycin #Moleculin #MBRX

Moleculin's Groundbreaking Approval Marks Start of Phase 3 AML Clinical Trials in Europe Moleculin Biotech receives first regulatory approval in Europe to recruit participants for its pivotal Phase 3 trial aimed at treating relapsed acute myeloid leukemia.

Moleculin's Groundbreaking Approval Marks Start of Phase 3 AML Clinical Trials in Europe #United_States #Houston #AML #Annamycin #Moleculin